OLŠOVSKÝ, Jindřich. Kardiovaskulární bezpečnost inkretinové terapie diabetes mellitus (Cardiovascular safety of incretin-based therapy of diabetes mellitus). In Farmakoterapie. Praha: Farmakon Press, 2017, p. 144-149. ISSN 1801-1209.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Kardiovaskulární bezpečnost inkretinové terapie diabetes mellitus
Name (in English) Cardiovascular safety of incretin-based therapy of diabetes mellitus
Authors OLŠOVSKÝ, Jindřich (203 Czech Republic, guarantor, belonging to the institution).
Edition Praha, Farmakoterapie, p. 144-149, 6 pp. 2017.
Publisher Farmakon Press
Other information
Original language Czech
Type of outcome Popularizing texts and activities
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/17:00096555
Organization unit Faculty of Medicine
ISSN 1801-1209
Keywords (in Czech) diabetes mellitus 2. typu; kardiovaskulární riziko; antidiabetika; inhibitory DPP-4; agonisté receptorů pro GLP-1
Keywords in English type 2 diabetes mellitus; cardiovascular risk; antidiabetic agents; DPP-4 inhibitors; GLP-1 receptor agonists
Tags EL OK
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 19/3/2018 16:12.
Abstract
K cílům léčby diabetes mellitus patří i snížení kardiovaskulární (KV) morbidity a mortality. Kardiovaskulárnímu riziku u diabetiků je proto věnována značná pozornost, zejména možnosti terapeuticky jej ovlivnit, a to jak léčbou samotné hyperglykemie, tak komplexní terapií diabetů s ovlivněním všech rizikových faktorů, ale také způsobem antidiabetické léčby - tedy výběrem antidiabetika. Článek je zaměřen na současné poznatky o KV bezpečnosti inkretinové léčby v obou jejích podobách, tedy terapie působící na základě inhibice dipeptidylpeptidázy-4 (DPP-4) a na podkladě agonismu receptorů pro glukagonu podobný peptid 1 (GLP-1).
Abstract (in English)
One of the objective of diabetes mellitus therapy is to reduce cardiovascular (CV) morbidity and mortality. This is the reason why the cardiovascular risk in patients with diabetes receives significant attention, especially the possibilities to influence it therapeutically, both through the therapy of hyperglycaemia itself and comprehensive modification of all risk factors, but also through the manner of antidiabetic therapy - i.e. through the selection of a particular antidiabetic agent. The article focuses on the current insights regarding CV safety of incretin-based therapy in both its forms, that is therapy acting based on the inhibition of dipeptidyl peptidase-4 (DPP-4) and on glucagon-like peptide 1 receptor (GLP-1) agonism.
PrintDisplayed: 6/5/2024 23:28